A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

Exclusion Criteria

• •Active concomitant disease, with exception of eczema
• •Expected onset of seasonal allergy before the administration of the last dose of study medication
• •History of severe exacerbation within 3 years of Day 0
• •Recorded use of inhaled short acting beta 2 agonist medication for symptoms within 14 days of Day 0 of: More than 6 doses per day on any 1 day or more than 3 doses per day on 6 or more days
• •Any medication other than: inhaled short-acting beta 2 agonist, inhaled corticosteroids, topic eczema treatments (with the exception of fluorinated corticosteroid, dermatological preparations which are not permitted), hormone replacement therapy, vitamin preparation/food supplements, occasional use of proton pump inhibitors, ranitidine, cimetidine, antacids or over-the-counter analgesics
• •Treatment within 6 months of Day 0 with any of the following: methylxanthines, inhaled cromones, leukotriene modifiers, anti- immunoglobulin E (IgE), anticholinergics, ketotifen, oral short acting B2 agonists, long-acting B2 agonists, oral or injected corticosteroids
• •Treatment of atopic symptoms, other than eczema, within 4 weeks of Day 0
• •History of medication that might carry-over effects into the study
• •Previously received monoclonal antibody, or a similar related protein, that might sensitize to CAT-354
• •Participation in another study within three months of the start of the study or 5 half lives of the previously administered investigational medicinal product (IMP), whichever is longer
• •Lower respiratory tract infection within 4 weeks of Day-14
• •Any acute illness in the two weeks before Day 0
• •Current smokers, those who have smoked in previous year, and those with smoking history of greater than or equal to 10 pack years
• •Considered by the investigator to be at risk of transmitting, through blood, the agents responsible for infectious diseases
• •Blood donation (550 ml) in the previous 2 months
• •Excessive intake of alcohol (more than 21 units a week for females or 28 units a week for males)
• •The subject's general practitioner has suggested a reason the subject should not participate in the study
• •The Investigator considers the subject should not take part for any reason.